The identification of LS carriers is currently based on the germline MMR and EPCAM testing of individuals with dMMR tumors or fulfilling clinical criteria, but the most efficient and sensitive strategies to select patients among CRC probands to whom it should be offered are yet not well defined (2). This evidence concerns the gene MRC1 and colorectal carcinoma.